Veteran creator Asmongold warns Twitch is nearing a breaking point due to "nuisance streaming," where creators engage in reckless stunts and harassment for viral moments. He fears a tragic, potentially lethal, incident will occur if the platform doesn't crack down on this behavior, which he believes is rewarded by Twitch's current moderation policies.
The contentious saga of Project Blue — a massive planned data-center campus in the Tucson area — has taken a new turn as the Arizona Corporation Commission approved an energy-supply agreement
VIU Foundation’s Giving Tuesday campaign raises more than $480,000 for students in need VIU in the News
The Metaverse was once regarded as the virtual future of the world. At the height of its popularity in the early 2020s, buyers boasted about how they had acquired virtual land next door to Hollywood legend. “Location, location” they exclaimed, like hot-footed regular world property buyers. But not anymore. The Metaverse has become “so yesterday” [...]
The Metaverse was once regarded as the virtual future of the world. At the height of its popularity in the early 2020s, buyers boasted about how they had acquired virtual land next door to Hollywood legend. “Location, location” they exclaimed, like hot-footed regular world property buyers. But not anymore. The Metaverse has become “so yesterday” [...]
SAN FRANCISCO and SUZHOU, China, Dec. 5, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC).Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent, stated, "IBI363 and IBI343 represent our next-generation therapies designed to address critical unmet needs in global cancer treatment. With clear, aligned development plans, Innovent's deep understanding of these assets, combined with Takeda's extensive experience and strong development and commercialization capabilities, we are poised to maximize the clinical potential of these assets across multiple indications. We look forward to the collaboration with our partner going forward."Under the agreement:Innovent and Takeda will co-develop IBI363 globally, and co-commercialize IBI363 in the U.S., with Takeda leading the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent has granted Takeda exclusive commercialization rights for IBI363 outside Greater China and the U.S. Takeda has global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S.Innovent has also granted Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China.Additionally, Takeda receives an exclusive option to license global rights for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage, outside Greater China. Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance at premium, i.e., HK$112.56 per share. Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent is also eligible to receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses (40/60 Innovent/Takeda).Detailed information about the collaboration can be found at the official website of Innovent Biologics. About Innovent BiologicsInnovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).Forward-looking statementThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
Eddie Osei-Nketia, who is New Zealand's record holder in the 100 and 200 meters, completed his eligibility switch to Australia on Thursday.
Football icon Cristiano Ronaldo has made a significant move into the AI sector, announcing a high-profile investment and brand partnership with Perplexity AI. This fast-growing answer engine is currently redefining the way people search for information. The Perplexity deal combines Cristiano’s global influence and advanced technology, backed by a new “Perplexity x CR7” experience that [...]
This is so chic.
BELLEVUE, Wash.--(BUSINESS WIRE)--T-Mobile US, Inc. (NASDAQ: TMUS) (“T-Mobile” or “the Company”) announced today that the Company’s Board of Directors has declared a cash dividend of $1.02 per share on its issued and outstanding shares of common stock. The dividend is payable on March 12, 2026 to stockholders of record as of the close of business on February 27, 2026. About T-Mobile US, Inc. As the supercharged Un-carrier, T-Mobile US, Inc. (NASDAQ: TMUS) is powered by an award-winning 5G netwo
WhatsApp Business could potentially start charging users who want to link more than four devices to the same account in a future update.
A bug in Google Messages is causing severe battery drain and overheating on some devices. Here's a temporary fix while you wait for Google to push an update.
Redmi 10 Power Price in India: Redmi has launched its new smartphone Redmi 10 Power in India. The smartphone was launched along with Redmi 10A, on Wednesday, 20 April in India
The premium Alienware m15 R7 and m17 R5 highlight four new Ryzen-powered systems.
Apple is offering its new firmware update for the MagSafe accessory that promises to give you faster charging for the compatible iPhone models.
System apps with native call-recording functionality remain unaffected.
The OnePlus Nord 2T India launch may take place soon as the moniker has been spotted on the TDRA certification. The OnePlus Nord 2T's camera details have also been leaked. Here are the expected specifications of the device.
The iPhone 16 is likely to be the first Apple device to skip the camera notch.
Garena Free Fire Max redeem codes are 12-digit codes that are region-specific and can be used by players to gain an edge over rivals in every round of the battle royale game.
We are still not sure that no-charger policy will be limited to Narzo 50A Prime or it will be extended to other Realme budget, mid-segment and premium phones
